Bioequivalence evaluation of two cariprazine hard capsule formulations
Naunyn-Schmiedeberg's Archives of Pharmacology · 2026
DOI: 10.1007/s00210-026-05017-1 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Mamdouh R Rezk und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt. Hauptthemen laut MEDLINE: Antipsychotic Agents, Drugs, Generic, Piperazines. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Atco Pharma for Pharmaceutical Industries, Egypt, Cairo University.
Abstract (Originalsprache)
Cariprazine, a third-generation antipsychotic, is indicated for schizophrenia and bipolar I disorder. Affordable formulations are essential for improving access and adherence, particularly in resource-limited settings. We aimed to assess the bioequivalence, safety, and tolerability of a newly developed generic hard capsule Vocarzine (1.5 mg) compared to a branded reference product of cariprazine hard capsule (Reagila®) under fasting conditions in healthy adult participants. In a randomized, open-label, single-dose, two-period, two-sequence crossover design, 30 healthy male and female participants received a single oral dose of either the test or reference product, with 4-week washout period. Pharmacokinetics were evaluated using validated LC–MS/MS methods. Bioequivalence was concluded if the 90% confidence intervals (CIs) for the geometric mean ratios (GMRs) of peak plasma concentration (C max ) and area under the concentration–time curve from time zero to 72 h (AUC 0-72h ) fell within 80–125%. Twenty-nine participants completed the study. The GMR (90% CI) for C max was 91.92% (85.07–99.33%) and for AUC 0-72h was 92.85% (88.86–97.02%), both within the bioequivalence acceptance range (80–125%). Both formulations were well tolerated; mild nausea was the most common adverse event, and no serious adverse events were reported. The two hard capsule formulations were bioequivalent, in terms of rate and extent of absorption, with a comparable safety profile, supporting the use of vocarzine as a safe, effective, and potentially cost-saving alternative. Clinical trial number: The ClinicalTrials.gov registration number is NCT07121868, retrospectively registered on August 13, 2025.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
- Advanced Research Center (ARC), Nasr City, Cairo, Egypt.
- R&D Department, Atco Pharmaceutical Company, Cairo, Egypt.
- Clinical Pharmacy Department, Faculty of Pharmacy, Cairo University, Kasr El-Aini St., P.O. Box 11562, Cairo, Egypt. aya.abdelmagid@pharma.cu.edu.eg.
Förderung
- Atco Pharma for Pharmaceutical Industries, Egypt
- Cairo University
Zitieren
APA
Rezk, M. R., Badr, K. A., Hosny, A. A. E. H., & Abdel Magid, A. M. (2026). Bioequivalence evaluation of two cariprazine hard capsule formulations. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-026-05017-1
Vancouver
Rezk MR, Badr KA, Hosny AAEH, Abdel Magid AM. Bioequivalence evaluation of two cariprazine hard capsule formulations. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-026-05017-1
BibTeX
@article{Rezk2026,
author = {Rezk, Mamdouh R and Badr, Kamal A and Hosny, Ahmed Abd El Hamid and Abdel Magid, Aya M},
title = {Bioequivalence evaluation of two cariprazine hard capsule formulations},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
doi = {10.1007/s00210-026-05017-1}
}
EUVIMED